Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» esketamine
esketamine
Trump touted a new antidepressant as a solution for veterans. Only 15 have been treated
Stat
Mon, 01/6/20 - 10:09 am
Donald Trump
veterans
esketamine
major depression
Spravato
JNJ
Janssen
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
KHN
Tue, 06/11/19 - 11:41 pm
FDA
Janssen
Spravato
esketamine
major depressive disorder
Study Finds Ketamine Nasal Spray Effective For Treating Depression: What You Should Know
Forbes
Thu, 05/23/19 - 10:45 pm
depression
ketamine
esketamine
Spravato
JNJ
Janssen
ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’
Endpoints
Fri, 05/10/19 - 10:20 am
JNJ
drug pricing
antidepressants
esketamine
Spravato
ICER
J&J prices ketamine-like depression treatment at $590-$885 for two doses
Reuters
Fri, 03/8/19 - 09:35 am
JNJ
Spravato
depression
drug pricing
esketamine
FDA approves Janssen's fast-acting depression therapy esketamine
BioCentury
Wed, 03/6/19 - 12:43 am
FDA
Spravato
esketamine
Janssen
JNJ
major depression
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
Yahoo/Benzinga
Sun, 03/3/19 - 07:09 pm
IPOs
biotech
JNJ
Janssen
esketamine
Shockwave Medical
earnings
Sensen Bio
MyoKardia
The psychiatry field is buzzing with anticipation — and hesitation — about esketamine for depression
Stat
Wed, 02/20/19 - 09:50 am
major depression
esketamine
JNJ
FDA
psychiatrists
FDA experts offer a big thumbs up for J&J’s flawed application to market esketamine for major depression — but trial failures, safety questions spur concerns
Endpoints
Tue, 02/12/19 - 04:21 pm
JNJ
FDA
advisory panels
esketamine
major depression
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Sun, 02/10/19 - 11:08 pm
Motif Biosciences
Iclaprim
Merck
Keytruda
melanoma
JNJ
esketamine
ASCO
Pfizer
Veru. earnings
Aveo Pharmaceuticals
Calithera Biosciences
Approving J&J's new depression drug would be an unusual move for the FDA
BioPharma Dive
Sun, 02/10/19 - 01:49 pm
JNJ
esketamine
FDA
advisory panels
J&J’s Esketamine for Depression Faces an FDA Panel Next Week
BioSpace
Sat, 02/9/19 - 12:34 am
JNJ
FDA
esketamine
major depression
J&J's Esketamine Fails to Meet Endpoint in Phase III Study
Yahoo/Zacks.com
Tue, 09/25/18 - 09:45 am
JNJ
clinical trials
esketamine
treatment-resistant depression
J&J execs say new launches and label expansions will fuel 'above-market' growth through 2021
Fierce Pharma
Fri, 09/14/18 - 09:52 am
JNJ
label expansions
esketamine
erdafitinib
J&J racks up a fresh set of positive pivotal data for depression drug esketamine — but questions linger on safety
Endpoints
Thu, 05/31/18 - 08:11 pm
JNJ
esketamine
major depression
J&J’s Janssen touts Ph3 data for antidepressant nasal spray
Drug Delivery Business News
Mon, 05/7/18 - 09:37 am
JNJ
Janssen
esketamine
depression
With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med esketamine
Endpoints
Sat, 05/5/18 - 11:03 am
JNJ
esketamine
major depression
JNJ's Esketamine Demonstrates Significantly Rapid Improvements in Depressive Symptoms and Suicidality in Phase 2 Study
CP Wire
Mon, 04/16/18 - 04:11 pm
JNJ
esketamine
depression
major depression
JNJ's Esketamine Demonstrates Significantly Rapid Improvements in Depressive Symptoms and Suicidality in Phase 2 Study
Mon, 04/16/18 - 04:10 pm
JNJ
esketamine
depression
major depression
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Motley Fool
Wed, 04/4/18 - 10:07 pm
Alkermes
JNJ
ALKS-5461
esketamine
major depressive disorder
Pages
1
2
next ›
last »